Mar 01, 2021 08:58 PM (GMT+8) · EqualOcean
Tan Xiaobing, fund manager of Equity Investment Department of Great Wall Fund, said at the 2021 spring investment strategy meeting of Great Wall Fund that at present, the valuation of some companies in the pharmaceutical sector is on the high side, which is mainly caused by two reasons: one is the high valuation resonance of A-share Baima shares, and the other is the comparative advantage of pharmaceutical fundamentals. In this context, in the future, the high valuation of the pharmaceutical sector will become the norm, there will be fluctuations, but it will not disappear. "However, there are still some pharmaceutical segments with strong attractive valuation, and those companies with poor expectations and cognition will also have investment opportunities in the future."